查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1605835

SGLT2抑制剂市场，规模，占有率，趋势，产业分析报告:各适应症，药物，各流通管道，各地区 - 市场预测 2025年～2034年

SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report: By Indication (Cardiovascular, Chronic Kidney Disease, Type 2 Diabetes, and Others), Drug, Distribution Channel, and Region - Market Forecast, 2025 - 2034
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，到2034年，SGLT2抑制剂的全球市场规模预计将达到327.5亿美元。该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂市场是全球製药业的关键参与者，受 2 型糖尿病 (T2D)、心臟衰竭和慢性肾病 (CKD) 发病率不断上升的推动。 SGLT2 抑制剂是一类透过抑制钠-葡萄糖协同转运蛋白 2 发挥作用的药物，钠-葡萄糖协同转运蛋白 2 是一种负责将葡萄糖从肾臟重新吸收到血液中的蛋白质。

SGLT2 抑制剂的市场正在经历显着成长，因为它们能够透过抑制肾臟中的葡萄糖重吸收来降低血糖水平，并且在治疗 2 型糖尿病 (T2D) 方面的疗效不断增强。这一增长是由肥胖率上升、久坐的生活方式、人口老化和不健康的饮食习惯所推动的。遗传倾向、都市化和经济差距也促使北美和世界各地糖尿病病例的快速增加。这增加了对 SGLT2 抑制剂的需求。

随着糖尿病患者寻求有效的治疗方法来控制病情并降低严重併发症的风险，COVID-19 大流行进一步加速了 SGLT2 抑制剂的采用。此外，大流行促使网上药局的使用激增，使这些药物更容易获得。此外，有利的报销政策、监管部门的批准和配方的不断创新正在进一步增强市场。

SGLT2抑制剂市场报告亮点

2024年，第2型糖尿病在SGLT2抑制剂市场中占据最大的销售占有率。城市化进程的加速往往会促使生活方式的改变，例如体力活动减少、加工食品消费增加以及压力水平增加。这些因素导致肥胖和第 2 型糖尿病盛行率上升，大大推动了 SGLT2 抑制剂市场的发展。

在预测期内，线上药局市场的复合年增长率最高。由于线上营运相关的管理成本降低，线上药局通常会提供有竞争力的药物价格和折扣。

2024年，由于慢性压力增加和精神状态恶化，北美SGLT2抑制剂市场占据最大市场。此外，北美糖尿病盛行率的增加也增加了对 SGLT2 抑制剂的需求。

亚太地区是市场成长最快的地区。该地区各国政府正在增加对医疗基础设施的投资，以改善医疗服务的取得和品质。这些努力正在支持医药市场和 SGLT2 抑制剂等药物的采用。

目录

第1章 简介

第2章 摘要整理

第3章 调查手法

第4章 全球SGLT2抑制剂市场洞察

  • 流通管道概述
  • SGLT2抑制剂市场动态
    • 促进因素和机会
      • 全球老化的加剧正在推动市场成长
      • 新药审批量增加推动市场前景
    • 阻碍因素与课题
      • 高额的医药品
  • PESTEL分析
  • SGLT2抑制剂市场流通管道趋势
  • 价值链分析
  • COVID-19影响分析

第5章 全球SGLT2抑制剂市场:各适应症

  • 主要调查结果
  • 简介
  • 心臟血管
  • 慢性肾臟病(CKD)
  • 第二型糖尿病
  • 其他

第6章 全球SGLT2抑制剂市场:药物

  • 主要调查结果
  • 简介
  • farushiga(Dapagliflozin)
  • inpefa(sotagurifurojin)
  • Invokana(Canagliflozin)
  • Jardiance(Empagliflozin)
  • Qtern(Dapagliflozin/sakisaguripuchin)
  • 其他的SGLT2抑制剂

第7章 全球SGLT2抑制剂市场:各流通管道

  • 主要调查结果
  • 简介
  • 医院药局
  • 线上药局
  • 零售药局

第8章 全球SGLT2抑制剂市场:各地区

  • 主要调查结果
  • 简介
    • SGLT2抑制剂市场评估:地区，2020～2034年
  • 北美
    • 北美:各适应症，2020～2034年
    • 北美:各流通管道，2020年～2034年
    • 北美:各药物，2020～2034年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲:各适应症，2020～2034年
    • 欧洲:各流通管道，2020～2034年
    • 欧洲:各药物，2020～2034年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 亚太地区:各适应症，2020年～2034年
    • 亚太地区:各流通管道，2020～2034年
    • 亚太地区:各药物，2020年～2034年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东·非洲
    • 中东·非洲:各适应症，2020～2034年
    • 中东·非洲:各流通管道，2020～2034年
    • 中东·非洲:各药物，2020～2034年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲
  • 南美
    • 南美:各适应症，2020～2034年
    • 南美:各流通管道，2020～2034年
    • 南美:各药物，2020～2034年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美国家

第9章 竞争情形

  • 扩大和收购的分析
    • 扩大
    • 收购
  • 联盟/合作/协定/公开

第10章 企业简介

  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson Services, Inc.(Janssen Pharmaceuticals, Inc.)
  • Lexicon Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Sanofi
  • TheracosBio, LLC
Product Code: PM5187

The global SGLT2 inhibitors market size is expected to reach USD 32.75 billion by 2034, according to a new study by Polaris Market Research. The report "SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report, By Indication (Cardiovascular, Chronic Kidney Disease (CKD), Type 2 Diabetes, and Others), Drug, Distribution Channel, and Region; Segment Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The sodium-glucose cotransporter 2 (SGLT2) inhibitors market has emerged as a significant segment of the global pharmaceutical industry, driven by the increasing prevalence of type 2 diabetes (T2D), heart failure, and chronic kidney diseases (CKD). SGLT2 inhibitors are a class of drugs that work by blocking the sodium-glucose cotransporter 2, a protein responsible for reabsorbing glucose from the kidneys into the bloodstream

The market for SGLT2 inhibitors is experiencing significant growth due to their increasing efficacy in treating type 2 diabetes (T2D) by inhibiting glucose reabsorption in the kidneys and thereby lowering blood sugar levels. This expansion is attributed to the increasing rising obesity rates, sedentary lifestyles, aging populations, and unhealthy diets. Genetic predisposition, urbanization, and economic differences also contribute to the surge in diabetes cases in North America and globally. Thereby boosting demand for SGLT2 inhibitors.

The COVID-19 pandemic has further accelerated the adoption of SGLT2 inhibitors as diabetic patients sought effective treatments to manage their condition and mitigate the risk of severe COVID-19 complications. Additionally, the pandemic has led to a surge in the use of online pharmacies, facilitating accessibility to these medications. Furthermore, favorable reimbursement policies, regulatory approvals, and ongoing innovations in drug formulations further bolster the market.

SGLT2 Inhibitors Market Report Highlights

In 2024, the type 2 diabetes segment accounted for the largest revenue share in the SGLT2 inhibitors market. Urbanization often leads to lifestyle changes characterized by decreased physical activity, increased consumption of processed foods, and higher stress levels. These factors contribute to the rising prevalence of obesity and type 2 diabetes, significantly driving the SGLT2 inhibitors market.

The online pharmacies segment is growing at the highest CAGR during the forecast period. Online pharmacies often offer competitive pricing and discounts on medications as a result of reduced overhead costs associated with online operations.

In 2024, North America SGLT2 inhibitors market accounted for the largest market due to the increasing chronic stress and poor mental. Additionally, the increasing prevalence of diabetes patients in North America has led to a higher demand for SGLT2 inhibitors in the region.

Asia Pacific accounted for the fastest growth in the market. Governments in the region are increasingly investing in healthcare infrastructure and initiatives to enhance access and quality. These efforts support pharmaceutical markets and the adoption of medications like SGLT2 inhibitors.

The global key market players include AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi; and TheracosBio, LLC.

Polaris Market Research has segmented the SGLT2 inhibitors market report based on indication, drug, distribution channel, and region:

By Indication Outlook (Revenue - USD Billion, 2020 - 2034)

  • Cardiovascular
  • Chronic Kidney Disease (CKD)
  • Type 2 Diabetes
  • Others

By Drug Outlook (Revenue - USD Billion, 2020 - 2034)

  • Farxiga (Dapagliflozin)
  • Inpefa (Sotagliflozin)
  • Invokana (Canagliflozin)
  • Jardiance (Empagliflozin)
  • Qtern (Dapagliflozin/Saxagliptin)
  • Other SGLT2 Inhibitors

By Distribution Channel Outlook (Revenue - USD Billion, 2020 - 2034)

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020 - 2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Vietnam
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global SGLT2 Inhibitors Market Insights

  • 4.1. SGLT2 Inhibitors Market - Distribution Channel Snapshot
  • 4.2. SGLT2 Inhibitors Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The Global Rise of the Aging Population is Driving Market Growth
      • 4.2.1.2. Rising New Drug Approvals Drive Market Outlook
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Medication
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. SGLT2 Inhibitors Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global SGLT2 Inhibitors Market, by Indication

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • 5.3. Cardiovascular
    • 5.3.1. Global SGLT2 Inhibitors Market, by Cardiovascular, by Region, 2020-2034 (USD Billion)
  • 5.4. Chronic Kidney Disease (CKD)
    • 5.4.1. Global SGLT2 Inhibitors Market, by Chronic Kidney Disease (CKD), by Region, 2020-2034 (USD Billion)
  • 5.5. Type 2 Diabetes
    • 5.5.1. Global SGLT2 Inhibitors Market, by Type 2 Diabetes, by Region, 2020-2034 (USD Billion)
  • 5.6. Others
    • 5.6.1. Global SGLT2 Inhibitors Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global SGLT2 Inhibitors Market, by Drug

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • 6.3. Farxiga (Dapagliflozin)
    • 6.3.1. Global SGLT2 Inhibitors Market, by Farxiga (Dapagliflozin), by Region, 2020-2034 (USD Billion)
  • 6.4. Inpefa (Sotagliflozin)
    • 6.4.1. Global SGLT2 Inhibitors Market, by Inpefa (Sotagliflozin), by Region, 2020-2034 (USD Billion)
  • 6.5.Invokana (Canagliflozin)
    • 6.5.1. Global SGLT2 Inhibitors Market, by Invokana (Canagliflozin), by Region, 2020-2034 (USD Billion)
  • 6.6. Jardiance (Empagliflozin)
    • 6.6.1. Global SGLT2 Inhibitors Market, by Jardiance (Empagliflozin), by Region, 2020-2034 (USD Billion)
  • 6.5. Qtern (Dapagliflozin/Saxagliptin)
    • 6.5.1. Global SGLT2 Inhibitors Market, by Qtern (Dapagliflozin/Saxagliptin), by Region, 2020-2034 (USD Billion)
  • 6.5. Other SGLT2 Inhibitors
    • 6.5.1. Global SGLT2 Inhibitors Market, by Other SGLT2 Inhibitors, by Region, 2020-2034 (USD Billion)

7. Global SGLT2 Inhibitors Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global SGLT2 Inhibitors Market, by Hospital Pharmacies, By Region, 2020-2034 (USD Billion)
  • 7.4. Online Pharmacies
    • 7.4.1. Global SGLT2 Inhibitors Market, by Online Pharmacies, By Region, 2020-2034 (USD Billion)
  • 7.5. Retail Pharmacies
    • 7.5.1. Global SGLT2 Inhibitors Market, by Retail Pharmacies, By Region, 2020-2034 (USD Billion)

8. Global SGLT2 Inhibitors Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. SGLT2 Inhibitors Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. SGLT2 Inhibitors Market - North America
    • 8.3.1. North America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
    • 8.3.2. North America: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.3. North America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.3.4. SGLT2 Inhibitors Market - U.S.
      • 8.3.4.1. U.S.: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.3.4.2. U.S.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.3.4.3. U.S.: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.3.5. SGLT2 Inhibitors Market - Canada
      • 8.3.5.1. Canada: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • 8.4. SGLT2 Inhibitors Market - Europe
    • 8.4.1. Europe: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
    • 8.4.2. Europe.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.3. Europe: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.4.4. SGLT2 Inhibitors Market - UK
      • 8.4.4.1. UK: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.4.4.2. UK.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.4.5. SGLT2 Inhibitors Market - France
      • 8.4.5.1. France: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.4.5.2. France.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.4.5.3. France: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.4.6. SGLT2 Inhibitors Market - Germany
      • 8.4.6.1. Germany: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.4.7. SGLT2 Inhibitors Market - Italy
      • 8.4.7.1. Italy: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.4.8. SGLT2 Inhibitors Market - Spain
      • 8.4.8.1. Spain: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.4.9. SGLT2 Inhibitors Market - Netherlands
      • 8.4.9.1. Netherlands: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.4.10. SGLT2 Inhibitors Market - Russia
      • 8.4.10.1. Russia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.4.11. SGLT2 Inhibitors Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • 8.5. SGLT2 Inhibitors Market - Asia Pacific
    • 8.5.1. Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.5.4. SGLT2 Inhibitors Market - China
      • 8.5.4.1. China: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.5.4.2. China.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.5.4.3. China: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.5.5. SGLT2 Inhibitors Market - India
      • 8.5.5.1. India: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.5.5.2. India.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.5.5.3. India: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.5.6. SGLT2 Inhibitors Market - Malaysia
      • 8.5.6.1. Malaysia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.5.7. SGLT2 Inhibitors Market - Japan
      • 8.5.7.1. Japan: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.5.8. SGLT2 Inhibitors Market - Indonesia
      • 8.5.8.1. Indonesia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.5.9. SGLT2 Inhibitors Market - South Korea
      • 8.5.9.1. South Korea: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.5.10. SGLT2 Inhibitors Market - Australia
      • 8.5.10.1. Australia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.5.11. SGLT2 Inhibitors Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • 8.6. SGLT2 Inhibitors Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.6.4. SGLT2 Inhibitors Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.6.5. SGLT2 Inhibitors Market - UAE
      • 8.6.5.1. UAE: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.6.6. SGLT2 Inhibitors Market - Israel
      • 8.6.6.1. Israel: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.6.7. SGLT2 Inhibitors Market - South Africa
      • 8.6.7.1. South Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.6.8. SGLT2 Inhibitors Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • 8.7. SGLT2 Inhibitors Market - Latin America
    • 8.7.1. Latin America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
    • 8.7.2. Latin America.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.7.4. SGLT2 Inhibitors Market - Mexico
      • 8.7.4.1. Mexico: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.7.5. SGLT2 Inhibitors Market - Brazil
      • 8.7.5.1. Brazil: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.7.6. SGLT2 Inhibitors Market - Argentina
      • 8.7.6.1. Argentina: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
    • 8.7.7. SGLT2 Inhibitors Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AstraZeneca
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Boehringer Ingelheim International GmbH
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bristol-Myers Squibb Company
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Eli Lilly and Company
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Glenmark Pharmaceuticals Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Lexicon Pharmaceuticals, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Merck & Co., Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Sanofi
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. TheracosBio, LLC
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 2 Global SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 3 Global SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 4 SGLT2 Inhibitors Market Assessment, By Geography, 2020-2034 (USD Billion)
  • Table 5 North America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 6 North America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 7 North America: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 8 U.S.: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 9 U.S.: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 10 U.S.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 11 Canada: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 12 Canada: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 13 Canada: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 14 Europe: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 15 Europe: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 16 Europe: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 17 UK: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 18 UK: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 19 UK: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 20 France: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 21 France: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 22 France: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 23 Germany: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 24 Germany: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 25 Germany: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 26 Italy: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 27 Italy: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 28 Italy: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 29 Spain: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 30 Spain: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 31 Spain: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 32 Netherlands: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 33 Netherlands: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 34 Netherlands: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 35 Russia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 36 Russia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 37 Russia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 40 Rest of Europe: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 43 Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 44 China: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 45 China: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 46 China: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 47 India: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 48 India: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 49 India: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 50 Malaysia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 51 Malaysia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 52 Malaysia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 53 Japan: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 54 Japan: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 55 Japan: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 56 Indonesia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 57 Indonesia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 58 Indonesia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 59 South Korea: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 60 South Korea: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 61 South Korea: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 62 Australia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 63 Australia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 64 Australia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 67 Rest of Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 70 Middle East & Africa: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 73 Saudi Arabia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 74 UAE: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 75 UAE: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 76 UAE: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 77 Israel: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 78 Israel: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 79 Israel: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 80 South Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 81 South Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 82 South Africa: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 85 Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 86 Latin America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 87 Latin America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 88 Latin America: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 89 Mexico: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 90 Mexico: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 91 Mexico: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 92 Brazil: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 93 Brazil: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 94 Brazil: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 95 Argentina: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 96 Argentina: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 97 Argentina: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
  • Table 100 Rest of Latin America: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)

List of Figures

  • Figure 1. Global SGLT2 Inhibitors Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Indication
  • Figure 7. Global SGLT2 Inhibitors Market, by Indication, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Drug
  • Figure 9. Global SGLT2 Inhibitors Market, by Drug, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global SGLT2 Inhibitors Market, by Distribution Channel, 2024 & 2034 (USD Billion)